Amgen Provides Ambitious Update On Biosimilars Business

CEO Says Company Expects To Double Biosimilar Revenues To Around $4bn By 2030

 
• By Chloe Kent
  
Amgen offices at Cambridge Science Park
Amgen has restated its ambitions to double the value of its biosimilars business by 2030 • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products